糖尿病患者的血压控制目标：临床流行病学研究分析与相关指南的更新解读

doi:10.16150/j.1671-2870.2018.01.001

摘要/Abstract

中图分类号:

R587.1

宁光. 糖尿病患者的血压控制目标：临床流行病学研究分析与相关指南的更新解读[J]. 诊断学理论与实践, 2018, 17(01): 1-4.

[1] Xu Y, Wang L, He J, et al.Prevalence and control of dia-betes in Chinese adults[J]. JAMA,2013,310(9):948-959.
[2] 中华医学会糖尿病分会. 中国2型糖尿病防治指南(2013年版)[J]. 中华糖尿病杂志,2014,6(7):447-498.
[3] Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group[J]. BMJ,1998,317(7160):703-713.
[4] Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial[J]. Lancet,2007,370(9590):829-840.
[5] Forouzanfar MH, Liu P, Roth GA, et al.Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015[J]. JAMA,2017,317(2):165-182.
[6] Adler AI, Stratton IM, Neil HA, et al.Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study[J]. BMJ,2000,321(7258):412-419.
[7] Hansson L, Zanchetti A, Carruthers SG, et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group[J]. Lancet,1998,351(9118):1755-1762.
[8] Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators[J]. Lancet,2000,355(9200):253-259.
[9] Lindholm LH, Ibsen H, Dahlöf B, et al.Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study(LIFE): a randomised trial against atenolol[J]. Lancet,2002,359(9311):1004-1010.
[10] Whelton PK, Barzilay J, Cushman WC, et al.Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial(ALLHAT)[J]. Arch Intern Med,2005,165(12):1401-1409.
[11] Chobanian AV, Bakris GL, Black HR, et al.The Se-venth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report[J]. JAMA, 2003,289(19):2560-2572.
[12] American Diabetes Association.Standards of medical care in diabetes--2006[J]. Diabetes Care,2006,29(Suppl 1):S4-S42.
[13] Bonny A, Lacombe F, Yitemben M, et al.The 2007 ESH/ESC guidelines for the management of arterial hypertension[J]. J Hypertens,2008,26(4):825-826.
[14] Ogihara T, Kikuchi K, Matsuoka H,et al.The Japanese Society of Hypertension Guidelines for the Management of Hypertension(JSH 2009)[J]. Hypertens Res,2009,32(1):103-107.
[15] 中国高血压防治指南修订委员会. 中国高血压防治指南(2005年修订版)[J]. 人民卫生出版社,2005:1-47.
[16] 中国高血压防治指南修订委员会.中国高血压防治指南2010[J]. 中华心血管病杂志,2011,39(7):579-616.
[17] ACCORD Study Group, Cushman WC, Evans GW, et al.Effects of intensive blood-pressure control in type 2 diabetes mellitus[J]. N Engl J Med,2010,362(17):1575-1585.
[18] Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease[J]. JAMA,2010,304(1):61-68.
[19] Emdin CA, Rahimi K, Neal B, et al.Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis[J]. JAMA,2015,313(6):603-615.
[20] Brunström M, Carlberg B.Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses[J]. BMJ,2016,352:i717.
[21] Bangalore S, Kumar S, Lobach I, et al.Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials[J]. Circulation,2011,123(24):2799-2810.
[22] Xie X, Atkins E, Lv J, et al.Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis[J]. Lancet,2016,387(10017):435-443.
[23] James PA, Oparil S, Carter BL, et al.2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appoin-ted to the Eighth Joint National Committee(JNC 8)[J]. JAMA,2014,311(5):507-520.
[24] ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension[J]. J Hypertens,2013,31(10):1925-1938.
[25] Shimamoto K, Ando K, Fujita T, et al.The Japanese Society of Hypertension Guidelines for the Management of Hypertension(JSH 2014)[J]. Hypertens Res,2014, 37(4):253-390.
[26] SPRINT Research Group, Wright JT Jr, Williamson JD, et al.A Randomized Trial of Intensive versus Standard Blood-Pressure Control[J]. N Engl J Med,2015,373(22):2103-2116.
[27] Leung AA, Nerenberg K, Daskalopoulou SS, et al.Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension[J]. Can J Cardiol,2016,32(5):569-588.
[28] Whelton PK, Carey RM, Aronow WS, et al.2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J/OL]. Hypertension.2017-11-13[2018-01-30].https://www.ncbi.nlm.nih.gov/pubmed/29133356.
[29] de Boer IH, Bangalore S, Benetos A, et al. Diabetes and Hypertension: A Position Statement by the American Diabetes Association[J]. Diabetes Care,2017,40(9):1273-1284.

糖尿病患者的血压控制目标：临床流行病学研究分析与相关指南的更新解读

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	沈小钰, 沙莎, 殷蕾, 周纬, 骆凝馨, 王雪峰. 儿童原发性肾病综合征动态血压变化特点的临床分析[J]. 诊断学理论与实践, 2022, 21(05): 613-618.
[2]	中华医学会内分泌学分会. 新型冠状病毒肺炎疫情下糖尿病管理专家建议[J]. 诊断学理论与实践, 2022, 21(02): 136-138.
[3]	陈煦阳, 顾卫琼. 胰岛素自身抗体临床检测应用局限及对策研究进展[J]. 诊断学理论与实践, 2022, 21(01): 95-98.
[4]	王广宇, 杨昕, 张立娟, 谭姣容. 住院新诊断2型糖尿病男性患者血浆总睾酮水平与骨钙素的相关性研究[J]. 诊断学理论与实践, 2021, 20(06): 573-578.
[5]	杨扬, 吴琴咪, 冯玉兰, 张蓓, 傅毅. 高血压患者脑血管周围间隙扩大和脑腔隙灶相关影响因素[J]. 诊断学理论与实践, 2021, 20(04): 372-377.
[6]	章淼滢, 罗飞宏. 儿童单基因糖尿病诊治进展及诊断策略[J]. 诊断学理论与实践, 2021, 20(03): 229-232.
[7]	范秋灵. 糖尿病肾病和非糖尿病慢性肾脏病患者应用钠-葡萄糖协同转运蛋白2抑制剂：预后评估及相关指南解读[J]. 诊断学理论与实践, 2021, 20(02): 130-137.
[8]	中国高血压联盟《动态血压监测指南》委员会. 2020中国动态血压监测指南[J]. 诊断学理论与实践, 2021, 20(01): 21-36.
[9]	李宙童, 张炜, 王继光. 家庭血压测量诊断白大衣高血压及隐匿性高血压的准确性研究[J]. 诊断学理论与实践, 2020, 19(05): 487-493.
[10]	王春花, 祁爽, 王敏. 原发性醛固酮增多症合并无痛性心肌梗死一例报告[J]. 诊断学理论与实践, 2020, 19(05): 528-530.
[11]	陈歆, 程艾邦, 许建忠, 李燕, 王继光. 中国高血压患者原发性醛固酮增多症的前瞻性筛查研究进展[J]. 诊断学理论与实践, 2020, 19(05): 450-453.
[12]	中国高血压联盟. 高血压患者原发性醛固酮增多症筛查诊治流程[J]. 诊断学理论与实践, 2020, 19(05): 454-459.
[13]	陈施吾, 窦荣花, 王玉凯, 王含, 王晓平, 陈先文, 陈玲, 王训, 屈洪党, 陈生弟, Susan Fox, 李燕, 王刚. 帕金森病血压管理专家共识[J]. 诊断学理论与实践, 2020, 19(05): 460-468.
[14]	赵红燕, 刘建民. 2019年《糖尿病患者骨折风险管理中国专家共识》解读[J]. 诊断学理论与实践, 2020, 19(03): 225-228.
[15]	黄永艳, 杨丽娜, 曹久妹, 王巍. 基于云数据的门诊高血压监测[J]. 诊断学理论与实践, 2020, 19(03): 319-324.